Profile data is unavailable for this security.
About the company
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.
- Revenue in USD (TTM)0.00
- Net income in USD4.50m
- Incorporated1996
- Employees2.00
- LocationPharmaCyte Biotech Inc3960 Howard Hughes Parkway, Suite 500LAS VEGAS 89169United StatesUSA
- Phone+1 (917) 595-2850
- Fax+1 (917) 595-2851
- Websitehttps://pharmacyte.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lyra Therapeutics Inc | 1.47m | -97.61m | 11.65m | 87.00 | -- | 0.5651 | -- | 7.92 | -1.51 | -1.51 | 0.0229 | 0.315 | 0.0148 | -- | -- | 16,715.91 | -97.94 | -58.01 | -118.22 | -68.69 | -- | -- | -6,635.76 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Viaderma Inc | 17.80m | 2.31m | 11.72m | 75.00 | 0.0006 | 0.00004 | 2.17 | 0.6585 | 16.84 | 16.84 | 129.62 | 255.59 | 0.4126 | 24.69 | 1.21 | 237,331.30 | 5.36 | -- | 6.53 | -- | 28.90 | -- | 12.99 | -- | 2.07 | 5.66 | 0.1718 | -- | -29.15 | -- | -40.70 | -- | -- | -- |
| Aspira Women's Health Inc | 8.92m | -15.95m | 11.73m | 64.00 | -- | -- | -- | 1.31 | -1.45 | -1.45 | 0.801 | -0.2892 | 1.53 | 15.11 | 5.79 | 139,421.90 | -273.16 | -110.58 | -3,758.30 | -151.88 | 57.84 | 45.23 | -178.80 | -334.08 | 0.5542 | -17,354.00 | -- | -- | 11.85 | 24.56 | 44.15 | -- | -26.65 | -- |
| Protext Mobility Inc | 750.00 | -2.21m | 11.87m | 4.00 | -- | -- | -- | 15,824.20 | -0.4692 | -0.4692 | 0.00001 | -0.0102 | 0.0405 | -- | -- | -- | -9,400.97 | -1,587.94 | -- | -- | 86.67 | -530.19 | -232,392.00 | -17,498.83 | 0.0002 | -1.36 | -- | -- | -93.98 | -63.09 | 27.35 | -- | -- | -- |
| Sol Gel Technologies Ltd | 11.71m | -9.57m | 12.29m | 36.00 | -- | 0.354 | -- | 1.05 | -0.3435 | -0.3435 | 0.4202 | 1.25 | 0.2522 | -- | 3.34 | 325,194.40 | -20.62 | -31.60 | -23.40 | -35.49 | -- | -- | -81.75 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Sensei Biotherapeutics Inc | 0.00 | -29.80m | 12.53m | 28.00 | -- | 0.2736 | -- | -- | -1.19 | -1.19 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -44.18 | -47.03 | -48.36 | -54.33 | -- | -- | -- | -- | -- | -- | 0.0222 | -- | -- | -- | 29.82 | -- | 42.16 | -- |
| AIM ImmunoTech Inc | 201.00k | -28.05m | 12.74m | 26.00 | -- | 1.87 | -- | 63.39 | -0.5703 | -0.5703 | 0.004 | 0.1068 | 0.0082 | -- | 12.18 | 7,730.77 | -113.70 | -45.64 | -149.16 | -48.35 | 71.14 | -231.75 | -13,952.74 | -11,695.01 | -- | -- | 0.3018 | -- | 43.26 | -11.26 | -48.94 | -- | 35.73 | -- |
| HST Global Inc | 0.00 | -123.45k | 12.80m | 1.00 | -- | -- | -- | -- | -0.0209 | -0.0209 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -3,300.80 | -5,836.01 | -- | -- | -- | -- | -- | -- | -- | -27.31 | 5.81 | -- | -- | -- | -0.7858 | -- | -- | -- |
| Inhibitor Therapeutics Inc | 0.00 | -3.08m | 12.92m | 3.00 | -- | 3.79 | -- | -- | -0.0179 | -0.0179 | 0.00 | 0.0198 | 0.00 | -- | -- | 0.00 | -38.42 | 27.48 | -38.90 | 32.70 | -- | -- | -- | -- | -- | -- | 0.00 | 0.00 | -- | -- | -125.39 | -- | -- | -- |
| NRX Pharmaceuticals Inc | 0.00 | -20.39m | 13.01m | 2.00 | -- | -- | -- | -- | -1.69 | -1.69 | 0.00 | -1.65 | 0.00 | -- | -- | -- | -231.96 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -104.47 | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Pharmacyte Biotech Inc | 0.00 | 4.50m | 13.21m | 2.00 | 3.40 | 0.2782 | 2.94 | -- | 0.5058 | 0.5058 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | 35.90 | -7.42 | 38.19 | -7.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -299.38 | -- | -- | -- |
| Traws Pharma Inc | 226.00k | -140.79m | 13.58m | 16.00 | -- | -- | -- | 60.11 | -141.34 | -141.34 | 0.2473 | -0.6719 | 0.0126 | -- | 0.2113 | 14,125.00 | -782.70 | -63.43 | -1,568.46 | -85.72 | -- | -- | -62,294.25 | -3,257.92 | -- | -- | -- | -- | 0.00 | -28.72 | 0.0844 | -- | -- | -- |
| Cingulate Inc | 0.00 | -16.35m | 14.39m | 13.00 | -- | 1.13 | -- | -- | -70.83 | -70.83 | 0.00 | 3.95 | 0.00 | -- | -- | 0.00 | -168.10 | -- | -268.55 | -- | -- | -- | -- | -- | -- | -141.37 | 0.0007 | -- | -- | -- | -33.14 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -3.31m | 14.83m | 9.00 | -- | -- | -- | -- | -0.4357 | -0.4357 | 0.00 | -3.10 | 0.00 | -- | -- | 0.00 | -6.25 | -49.89 | -6.75 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| IN8BIO, Inc. | 0.00 | -31.88m | 15.04m | 31.00 | -- | 1.75 | -- | -- | -0.7581 | -0.7581 | 0.00 | 0.1836 | 0.00 | -- | -- | 0.00 | -151.16 | -74.18 | -188.31 | -84.42 | -- | -- | -- | -- | -- | -- | 0.1233 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
Data as of Nov 21 2024. Currency figures normalised to PharmaCyte Biotech Inc's reporting currency: US Dollar USD
12.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| K2 & Associates Investment Management, Inc.as of 30 Sep 2024 | 209.27k | 2.73% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 192.39k | 2.51% |
| Iroquois Capital Management LLCas of 17 Jul 2024 | 178.65k | 2.33% |
| Geode Capital Management LLCas of 30 Sep 2024 | 168.20k | 2.19% |
| Equitec Proprietary Markets LLCas of 30 Sep 2024 | 82.73k | 1.08% |
| Renaissance Technologies LLCas of 30 Sep 2024 | 49.70k | 0.65% |
| G1 Execution Services LLCas of 30 Sep 2024 | 35.23k | 0.46% |
| Schonfeld Strategic Advisors LLCas of 30 Sep 2024 | 25.90k | 0.34% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 22.22k | 0.29% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 19.21k | 0.25% |
More ▼
Data from 30 Sep 2024 - 14 Oct 2024Source: FactSet Research Systems Inc.
